The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

Jill S. Lindberg, Sharon M. Moe, William G. Goodman, Jack W. Coburn, Stuart M. Sprague, Wei Liu, Peter W. Blaisdell, Robert M. Brenner, Stewart A. Turner, Kevin J. Martin

Research output: Contribution to journalArticle

209 Scopus citations


Background. A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism. Methods. Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus. Results. The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 ± 280.1 pg/mL vs. 637 ± 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH ≥30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study. Conclusions. The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism.

Original languageEnglish (US)
Pages (from-to)248-254
Number of pages7
JournalKidney international
Issue number1
StatePublished - Jan 1 2003


  • Calcimimetic
  • Calcium x phosphorus
  • Calcium-sensing receptor
  • End-stage renal disease
  • Parathyroid hormone
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism'. Together they form a unique fingerprint.

  • Cite this

    Lindberg, J. S., Moe, S. M., Goodman, W. G., Coburn, J. W., Sprague, S. M., Liu, W., Blaisdell, P. W., Brenner, R. M., Turner, S. A., & Martin, K. J. (2003). The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney international, 63(1), 248-254.